OrthoPediatrics Secures FDA Approval for 3P Small-Mini Pediatric Plating System
Key Insights
OrthoPediatrics Corp. (search) received FDA approval for its 3P Pediatric Plating Platform Small-Mini System (search), marking the company's sixth regulatory clearance in 2025.
The versatile plate and screw solution features variable-angle locking implants in sizes ranging from 2.0mm to 3.5mm, specifically designed for pediatric trauma (search) and deformity (search) surgeries.
The system incorporates specialized instruments, streamlined tray layouts, and color-coding to optimize operating room efficiency for pediatric orthopedic procedures.
OrthoPediatrics Corp. (search) announced FDA approval of its 3P Pediatric Plating Platform Small-Mini System (search) on October 28, 2025, representing the second system in the company's expanding 3P family and its sixth regulatory clearance this year. The Warsaw, Indiana-based company, which trades on Nasdaq under the ticker KIDS, focuses exclusively on advancing pediatric orthopedic solutions.
System Design and Clinical Applications
The 3P Small-Mini System delivers a comprehensive plate and screw solution featuring variable-angle locking implants engineered specifically for pediatric orthopedic surgeons. The platform supports trauma (search) and deformity (search) surgeries through procedure-specific and utility plates available in four sizes: 2.0mm, 2.4mm, 2.7mm, and 3.5mm.
The system incorporates specialized instruments, streamlined tray layouts, and color-coding designed to enhance surgical flow and optimize operating room efficiency. These features address the unique requirements of pediatric orthopedic procedures, where precision and efficiency are critical for patient outcomes.
Leadership Perspectives on Market Impact
Joe Hauser, OrthoPediatrics President of Trauma (search), Deformity (search) Correction and OPSB, emphasized the system's significance in addressing unmet medical needs. "This milestone represents another significant step forward in the 3P product development journey," Hauser stated. "Our engineering and surgeon design teams continue to demonstrate exceptional work in advancing the next 3P system following the successful launch of 3P Hip. This innovative platform is redefining how pediatric surgeons treat their patients, addressing a significant unmet medical need."
CEO David Bailey highlighted the company's accelerated regulatory timeline and comprehensive product development strategy. "This is the 6th FDA approval for the company in 2025, and was received ahead of our expectations, thanks to the dedication and excellence of our R&D team," Bailey commented. "We remain focused on delivering a comprehensive portfolio of innovative orthopedic solutions to expand our support to more pediatric patients."
Commercial Timeline and Market Strategy
OrthoPediatrics plans to move toward a limited market release in early 2026, building on the foundation established by the successful 3P Hip System launch. The Small-Mini System represents the second release in the broader 3P Pediatric Plating Platform, with additional systems planned for future development.
The company's comprehensive approach to pediatric orthopedics spans over 80 products across trauma (search) and deformity (search), scoliosis (search), and sports medicine procedures. Founded in 2006, OrthoPediatrics maintains a global sales organization focused exclusively on pediatric orthopedics, distributing products in the United States and over 70 international markets.